Cardiovascular Preclinical Deal Benchmarks (2026)
Median upfront of $51M with total deal values reaching $1.1B.
Median Upfront
$51M
Total Deal Value
$693M
Royalty Range
4.4%–8.8%
Territory Multiplier
1x
Understanding Cardiovascular Deal Benchmarks at Preclinical
Preclinical Cardiovascular licensing deals command a median upfront payment of $51M, with values ranging from $18M at the low end to $89M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the cardiovascular therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.
Total deal values — including milestones for development, regulatory, and commercial achievements — range from $312M to $1.1B, with a median of $693M. Royalty rates for cardiovascular assets at this stage typically fall between 4.4% and 8.8% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.
The Global territory applies a 1x multiplier to base deal economics. This accounts for market size, regulatory complexity, pricing environment, and competitive landscape differences across geographies. Licensors negotiating global rights should calibrate upfront expectations and milestone structures accordingly.
Full Market Analysis
Detailed deal economics, territory impact analysis, and royalty structure breakdown.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Full Benchmark Data
| Metric | Low | Median | High |
|---|---|---|---|
| Upfront Payment | $18M | $51M | $89M |
| Total Deal Value | $312M | $693M | $1.1B |
| Royalty Rate | 4.4% | — | 8.8% |
Comparable Deals
| Year | Licensor | Licensee | Upfront | Total Value | Deal Type |
|---|---|---|---|---|---|
| 2024 | BridgeBio Pharma | Astellas Pharma | $400M | $1.7B | licensing |
| 2024 | Alnylam Pharmaceuticals | Roche | $310M | $2.2B | licensing |
| 2023 | Cytokinetics | Royalty Pharma | $500M | $2.0B | licensing |
| 2023 | Ionis Pharmaceuticals | Novartis | $150M | $900M | licensing |
| 2023 | Tenaya Therapeutics | Roche | $60M | $1.2B | collaboration |
| 2024 | Verve Therapeutics | Eli Lilly | $60M | $560M | option |
| 2023 | Rocket Pharmaceuticals | N/A (standalone) | $0M | $650M | licensing |
| 2023 | CRISPR Therapeutics | Vertex Pharmaceuticals | $100M | $900M | collaboration |
| 2024 | Cardiol Therapeutics | N/A (standalone) | $0M | $250M | licensing |
| 2022 | MyoKardia | BMS | $13.1B | $13.1B | acquisition |
See All Comparable Deals
View 10 comparable Cardiovascular transactions with upfront payments, total values, and deal structures.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Frequently Asked Questions
What is the average upfront payment for Preclinical Cardiovascular deals?
How does Global territory affect Cardiovascular deal value?
What royalty rates are typical for Preclinical Cardiovascular licensing?
More Expert Insights
Royalty negotiation strategies and deal structure guidance.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Related Benchmarks
$131M upfront
Cardiovascular · Phase 1 · Global
$505M upfront
Cardiovascular · Phase 2 · Global
$1.4B upfront
Cardiovascular · Phase 3 · Global
$3.8B upfront
Cardiovascular · Approved · Global
$32M upfront
Oncology · Preclinical · Global
$32M upfront
Neurology/CNS · Preclinical · Global
$72M upfront
Immunology · Preclinical · Global
$77M upfront
Metabolic/Obesity · Preclinical · Global
Run Your Own Benchmark
These benchmarks are starting points. Get a customized valuation for your specific asset, indication, and deal structure.
Open SolidusCite This Data
Ambrosia Ventures. (2026). Cardiovascular Preclinical Deal Benchmarks (2026). Retrieved from https://solidus.ambrosiaventures.co/data/cardiovascular-preclinical-deals-global
<a href="https://solidus.ambrosiaventures.co/data/cardiovascular-preclinical-deals-global">Cardiovascular Preclinical Deal Benchmarks (2026)</a> — Ambrosia Ventures (2026)
<iframe src="https://solidus.ambrosiaventures.co/api/embed/chart?type=phase-upfront&ta=cardiovascular&theme=light" width="600" height="400" frameborder="0" style="border:1px solid #e2e8f0;border-radius:12px;"></iframe>
Data sourced from 1,600+ verified biopharma transactions. Updated monthly.